Oxazine derivatives and their use in the treatment of neurological disorders

Abstract

The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

1 - 4 . (canceled) 
     
     
         5 . A compound of the formula, or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
       
       in which
 X is O or S; 
 R 1  is hydrogen; cyano; halogen; (C 1-8 )alkyl; halogen-(C 1-8 )alkyl; (C 1-8 )alkoxy; halogen-(C 1-8 )alkoxy; (C 1-8 )alkylthio; halogen-(C 1-8 )alkylthio; (C 1-8 )alkoxy-(C 1-8 )alkyl; (C 1-8 )alkoxy-(C 1-8 )alkoxy; (C 1-8 )alkoxy-(C 1-8 )alkylthio; (C 1-8 )alkylthio-(C 1-8 )alkyl; (C 1-8 )alkylthio-(C 1-8 )alkoxy; (C 1-8 )alkylthio-(C 1-8 )alkylthio; (C 2-8 )alkenyl; or (C 2-8 )alkynyl; 
 R 2  is an aryl, heteroaryl or non-aromatic heterocyclyl group G 1 , which group G 1  is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, nitro, amino, aminocarbonyl, amino-(C 1-8 )alkyl, (C 1-4 )alkyl-amino-(C 1-8 )alkyl, di(C 1-4 )alkyl-amino-(C 1-8 )alkyl, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, hydroxy, oxo, (C 1-8 )alkoxy, halogen-(C 1-8 )alkoxy, (C 1-8 )alkylthio, halogen-(C 1-8 )alkylthio, (C 1-8 )alkoxy-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkoxy, (C 1-8 )alkoxy-(C 1-8 )alkylthio, (C 1-8 )alkylthio-(C 1-8 )alkyl, (C 1-8 )alkylthio-(C 1-8 )alkoxy, (C 1-8 )alkylthio-(C 1-8 )alkylthio, (C 2-8 )alkenyl, (C 2-8 )alkynyl, (C 2-8 )alkenoxy, (C 2-8 )alkynoxy and a (C 3-8 )cycloalkyl, aryl, heteroaryl or non-aromatic heterocyclyl group G 2 , which group G 2  is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, aminocarbonyl, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, hydroxy, (C 1-8 )alkoxy, halogen-(C 1-8 )alkoxy, (C 1-8 )alkylthio, halogen-(C 1-8 )alkylthio, (C 1-8 )alkoxy-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkoxy, (C 1-8 )alkoxy-(C 1-8 )alkylthio, (C 1-8 )alkylthio-(C 1-8 )alkyl, (C 1-8 )alkylthio-(C 1-8 )alkoxy, (C 2-8 )alkenyl and (C 2-8 )alkynyl; 
 R 3  is hydrogen; cyano; halogen; (C 1-8 )alkyl; halogen-(C 1-8 )alkyl; (C 1-8 )alkoxy; halogen-(C 1-8 )alkoxy; (C 1-8 )alkylthio; halogen-(C 1-8 )alkylthio; (C 1-8 )alkoxy-(C 1-8 )alkyl; (C 1-8 )alkoxy-(C 1-8 )alkoxy; (C 1-8 )alkoxy-(C 1-8 )alkylthio; (C 1-8 )alkylthio-(C 1-8 )alkyl; (C 1-8 )alkylthio-(C 1-8 )alkoxy; (C 1-8 )alkylthio-(C 1-8 )alkylthio; (C 2-8 )alkenyl; or (C 2-8 )alkynyl; 
 either 
 R 4  is hydrogen; cyano; halogen; (C 1-8 )alkyl; halogen-(C 1-8 )alkyl; (C 1-8 )alkoxy; halogen-(C 1-8 )alkoxy; (C 1-8 )alkylthio; halogen-(C 1-8 )alkylthio; (C 1-8 )alkoxy-(C 1-8 )alkyl; (C 1-8 )alkoxy-(C 1-8 )alkoxy; (C 1-8 )alkoxy-(C 1-8 )alkylthio; (C 1-8 )alkylthio-(C 1-8 )alkyl; (C 1-8 )alkylthio-(C 1-8 )alkoxy; (C 1-8 )alkylthio-(C 1-8 )alkylthio; (C 2-8 )alkenyl; or (C 2-8 )alkynyl; and 
 R 5  is hydrogen; cyano; halogen; (C 1-8 )alkyl; halogen-(C 1-8 )alkyl; (C 1-8 )alkoxy; halogen-(C 1-8 )alkoxy; (C 1-8 )alkylthio; halogen-(C 1-8 )alkylthio; (C 1-8 )alkoxy-(C 1-8 )alkyl; (C 1-8 )alkoxy-(C 1-8 )alkoxy; (C 1-8 )alkoxy-(C 1-8 )alkylthio; (C 1-8 )alkylthio-(C 1-8 )alkyl; (C 1-8 )alkylthio-(C 1-8 )alkoxy; (C 1-8 )alkylthio-(C 1-8 )alkylthio; (C 2-8 )alkenyl; or (C 2-8 )alkynyl; 
 or 
 R 4  and R 5 , taken together, are —C(H)═C(H)—C(H)═C(H)— or a (C 1-8 )alkylene group, in which (C 1-8 )alkylene group 1 or 2 —CH 2 — ring members are optionally replaced with hetero ring members independently selected from the group, consisting of —N(H)—, —N[(C 1-8 )alkyl]-, —O—, —S—, —S(═O)— or —S(═O) 2 —; 
 R 6  is hydrogen; (C 1-8 )alkyl; halogen-(C 1-8 )alkyl; hydroxy-(C 1-8 )alkyl; (C 1-8 )alkoxy-(C 1-8 )alkyl; mercapto-(C 1-8 )alkyl; (C 1-8 )alkylthio-(C 1-8 )alkyl; amino-(C 1-8 )alkyl; N—(C 1-8 )alkylamino-(C 1-8 )alkyl; N,N-di-[(C 1-8 )alkyl]amino-(C 1-8 )alkyl with two identical or different (C 1-8 )alkyl moieties in the N,N-di-[(C 1-8 )alkyl]amino moiety; (C 2-8 )alkenyl; or (C 2-8 )alkynyl; 
 E 1  is —C(R 7 )(R 8 )—C(R 9 )(R 10 )—; 
 E 2  is —C(R 11 )(R 12 )—; or —C(R 11 )(R 12 )—C(R 13 )(R 14 )—; 
 either 
 each of R 7  and R 8  is independently selected from the group, consisting of hydrogen, cyano, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkyl and (C 1-8 )alkylthio-(C 1-8 )alkyl; 
 or 
 R 7  and R 8 , taken together, are oxo or —CH 2 —CH 2 —; 
 either 
 each of R 9  and R 10  is independently selected from the group, consisting of hydrogen, cyano, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkyl and (C 1-8 )alkylthio-(C 1-8 )alkyl; 
 or 
 R 9  and R 10 , taken together, are oxo or —CH 2 —CH 2 —; 
 either 
 each of R 11  and R 12  is independently selected from the group, consisting of hydrogen, cyano, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkyl and (C 1-8 )alkylthio-(C 1-8 )alkyl; 
 or 
 R 11  and R 12 , taken together, are oxo or —CH 2 —CH 2 —; and 
 either 
 each of R 13  and R 14  is independently selected from the group, consisting of hydrogen, cyano, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkyl and (C 1-8 )alkylthio-(C 1-8 )alkyl; 
 or 
 R 13  and R 14 , taken together, are oxo or —CH 2 —CH 2 —. 
 
     
     
         6 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein X is O. 
     
     
         7 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 1  is hydrogen. 
     
     
         8 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 2  is a heteroaryl or aryl group which is optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group, consisting of cyano, nitro, amino, aminocarbonyl, amino-(C 1-8 )alkyl, (C 1-4 )alkyl-amino-(C 1-8 )alkyl, di(C 1-4 )alkyl-amino-(C 1-8 )alkyl, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, hydroxy, oxo, (C 1-8 )alkoxy, halogen-(C 1-8 )alkoxy, (C 1-8 )alkylthio, halogen-(C 1-8 )alkylthio, (C 1-8 )alkoxy-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkoxy, (C 1-8 )alkoxy-(C 1-8 )alkylthio, (C 1-8 )alkylthio-(C 1-8 )alkyl, (C 1-8 )alkylthio-(C 1-8 )alkoxy, (C 1-8 )alkylthio-(C 1-8 )alkylthio, (C 2-8 )alkenyl, (C 2-8 )alkynyl, (C 2-8 )alkenoxy and (C 2-8 )alkynoxy. 
     
     
         9 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 2  is a pyridyl or pyrazinyl group which is substituted by 1, 2, 3 or 4 substituents and wherein one of the substituents is located at the para position of the pyridyl or pyrazinyl group relative to the amide linker and wherein the substituents are independently selected from the group, consisting of cyano, nitro, amino, aminocarbonyl, amino-(C 1-8 )alkyl, (C 1-4 )alkyl-amino-(C 1-8 )alkyl, di(C 1-4 alkyl-amino-(C 1-8 )alkyl, halogen, (C 1-8 )alkyl, halogen-(C 1-8 )alkyl, hydroxy, oxo, (C 1-8 )alkoxy, halogen-(C 1-8 )alkoxy, (C 1-8 )alkylthio, halogen-(C 1-8 )alkylthio, (C 1-8 )alkoxy-(C 1-8 )alkyl, (C 1-8 )alkoxy-(C 1-8 )alkoxy, (C 1-8 )alkoxy-(C 1-8 )alkylthio, (C 1-8 )alkylthio-(C 1-8 )alkyl, (C 1-8 )alkylthio-(C 1-8 )alkoxy, (C 1-8 )alkylthio-(C 1-8 )alkylthio, (C 2-8 )alkenyl, (C 2-8 )alkynyl, (C 2-8 )alkenoxy and (C 2-8 )alkynoxy. 
     
     
         10 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 2  is a pyridyl or pyrazinyl group which is substituted by 1, 2, 3 or 4 substituents and wherein one of the substituents is located at the para position of the pyridyl or pyrazinyl group relative to the amide linker and wherein the substituents are independently selected from the group, consisting of deuterium, cyano, halogen, (C 1-6 )alkyl, deuterated (C 1-6 )alkyl, (C 1-6 )alkoxy, (C 1-6 )alkoxy-(C 1-6 )alkoxy, halogen-(C 1-6 )alkyl and (C 2-6 )alkynoxy. 
     
     
         11 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 3  is hydrogen. 
     
     
         12 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 4  is hydrogen or halogen. 
     
     
         13 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 5  is hydrogen or halogen. 
     
     
         14 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 6  is (C 1-3 )alkyl; or halogen-(C 1-3 )alkyl. 
     
     
         15 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein each of R 7  and R 8  is independently selected from hydrogen and fluoro and each of R 9  and R 10  is hydrogen. 
     
     
         16 . A compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, wherein E 2  is —C(R 11 )(R 12 )— and each of R 11  and R 12  is hydrogen. 
     
     
         17 . A compound according to  claim 5  which is selected from the group consisting of:
 5-Bromo-pyridine-2-carboxylic acid[3-((S)-3-amino-5-difluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 5-Bromo-pyridine-2-carboxylic acid[3-((S)-3-amino-5-difluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 5-Cyano-pyridine-2-carboxylic acid[3-(3-amino-5-trifluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 5-Bromo-pyridine-2-carboxylic acid[3-(3-amino-5-trifluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 N-(3-(3-amino-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-5-yl)-4-fluorophenyl)-5-chloropicolinamide; 
 5-Bromo-pyridine-2-carboxylic acid[3-(3-amino-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 3-Chloro-5-trifluoromethyl-pyridine-2-carboxylic acid[3-(3-amino-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide; 
 5-Bromo-3-methoxy-pyridine-2-carboxylic acid[3-(3-amino-6,6difluoro-5-methyl-2,5,6,7tetrahydro-[1,4]oxazepin-5-yl)-4 fluoro-phenyl]-amide; 
 5-Cyano-pyridine-2-carboxylic acid[3-(3-amino-6,6-difluoro-5 methyl-2,5,6,7-tetrahydro[1,4]oxazepin-5-yl)-4fluoro-phenyl]-amide; 
 and pharmaceutically acceptable salts thereof. 
 
     
     
         18 . A process for the preparation of a compound as defined in  claim 5  of the formula I, or a pharmaceutically acceptable salt thereof, comprising
 a) the reaction of a compound of the formula 
 
       
         
           
           
               
               
           
         
       
       in which R 1 , R 3 , R 4 , R 5 , R 6 , E 1  and E 2  are as defined for the formula I, or a pharmaceutically acceptable salt thereof, with a compound of the formula 
       
         
           
           
               
               
           
         
       
       in which R 2  is as defined for the formula I and L is a leaving group, or a pharmaceutically acceptable salt thereof,
 b) the optional reduction, oxidation or other functionalisation of the resulting compound, 
 c) the cleavage of any protecting group(s) optionally present and 
 d) the recovery of the so obtainable compound of the formula I in free form or in pharmaceutically acceptable salt form. 
 
     
     
         19 . A pharmaceutical composition comprising a compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, as active ingredient and a pharmaceutical carrier or diluent. 
     
     
         20 . A method for the treatment or prevention of neurological or vascular disorders related to beta-amyloid generation and/or aggregation in a subject in need of such treatment or prevention, which comprises administering to such subject a therapeutically effective amount of a compound according to  claim 5 , or a pharmaceutically acceptable salt thereof. 
     
     
         21 . A method for the treatment or prevention of Alzheimer's Disease, in a subject in need of such treatment or prevention, which comprises administering to such subject a therapeutically effective amount of a compound according to  claim 5 , or a pharmaceutically acceptable salt thereof. 
     
     
         22 . A pharmaceutical combination comprising a therapeutically effective amount of a compound according to  claim 5 , or a pharmaceutically acceptable salt thereof, and a second drug substance, for simultaneous or sequential administration.